Quadrivalent HPV vaccine effectiveness against cervical intraepithelial lesion grade 2 or worse in Norway: A registry-based study of 0,9 million Norwegian women

Madleen Orumaa; Elen Johanne Lahlum; Marie Gulla; Joseph Tota; Mari Nygård; Ståle Nygård

doi:10.1093/infdis/jiae209

Quadrivalent HPV vaccine effectiveness against cervical intraepithelial lesion grade 2 or worse in Norway: A registry-based study of 0,9 million Norwegian women

J Infect Dis. 2024 Apr 25:jiae209. doi: 10.1093/infdis/jiae209. Online ahead of print.

Authors

Madleen Orumaa¹, Elen Johanne Lahlum¹, Marie Gulla¹, Joseph Tota², Mari Nygård¹, Ståle Nygård¹

Affiliations

¹ Department of Research, Cancer Registry of Norway, Norway.
² Merck & Co., Inc., Rahway, NJ, USA.

PMID: 38658353
DOI: 10.1093/infdis/jiae209

Abstract

In Norway, single cohort vaccination with quadrivalent HPV (qHPV) vaccine targeting 12-year-old girls took place from 2009-2016. In 2020, the oldest vaccinated cohort was 23 years old and had approached the age where risk of being diagnosed with cervical intraepithelial lesion grade 2 or worse (CIN2+) increases rapidly. The aim of this cohort study was to assess direct qHPV vaccine effectiveness (VE) against CIN2+ among Norwegian women aged 16-30 in 2007-2020. By using population-based health registries and individual-level data on vaccination status and potential subsequent CIN2+ incidence, we found 82% qHPV VE among women vaccinated before the age of 17.

Keywords: Keyword: cervical high-grade lesions; population-based registry data; qHPV vaccine; vaccine effectiveness.